These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12474536)

  • 1. Expression of CD44 protein in renal cell carcinomas: association with p53 expression.
    Zolota V; Tsamandas AC; Melachrinou M; Batistatou A; Scopa C
    Urol Oncol; 2002; 7(1):13-7. PubMed ID: 12474536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD44 and P53 in renal cell carcinoma: association with tumor subtypes.
    Noroozinia F; Fahmideh AN; Yekta Z; Rouhrazi H; Rasmi Y
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):79-84. PubMed ID: 24434386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence.
    Gilcrease MZ; Guzman-Paz M; Niehans G; Cherwitz D; McCarthy JB; Albores-Saavedra J
    Cancer; 1999 Dec; 86(11):2320-6. PubMed ID: 10590373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.
    Sekino Y; Han X; Kobayashi G; Babasaki T; Miyamoto S; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Teishima J; Sakamoto N; Sentani K; Oue N; Yasui W; Matsubara A
    Oncology; 2021; 99(4):240-250. PubMed ID: 33588420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas.
    Gilcrease MZ; Truong L; Brown RW
    Hum Pathol; 1996 Dec; 27(12):1355-60. PubMed ID: 8958311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell Carcinoma.
    Sekino Y; Han X; Babasaki T; Miyamoto S; Kitano H; Kobayashi G; Goto K; Inoue S; Hayashi T; Teishima J; Sakamoto N; Sentani K; Oue N; Yasui W; Matsubara A
    Oncology; 2020; 98(10):689-698. PubMed ID: 32585672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of standard and variant CD44 in human lung cancer].
    Zhao H; Fang J; Du G
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Sep; 21(9):541-3. PubMed ID: 11360506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers.
    Haitel A; Wiener HG; Blaschitz U; Marberger M; Susani M
    Cancer; 1999 Apr; 85(7):1593-8. PubMed ID: 10193951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of p53 gene alteration in renal-cell cancer by micropreparation techniques of tumor specimens.
    Kuczyk MA; Serth J; Bokemeyer C; Jonassen J; Arndt H; Paeslack U; Werner M; Tan HK; Jonas U
    Int J Cancer; 1995 Dec; 64(6):399-406. PubMed ID: 8550242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of osteopontin and CD44 molecule in papillary renal cell tumors.
    Matusan K; Dordevic G; Mozetic V; Lucin K
    Pathol Oncol Res; 2005; 11(2):108-13. PubMed ID: 15999156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
    Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
    Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
    Mizera-Nyczak E; Dyszkiewicz W; Heider KH; Zeromski J
    Tumour Biol; 2001; 22(1):45-53. PubMed ID: 11054026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.
    Mikami S; Mizuno R; Kosaka T; Saya H; Oya M; Okada Y
    Int J Cancer; 2015 Apr; 136(7):1504-14. PubMed ID: 25123505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of CD44 isoforms in human renal cell carcinomas.
    Heider KH; Ratschek M; Zatloukal K; Adolf GR
    Virchows Arch; 1996 Jul; 428(4-5):267-73. PubMed ID: 8764936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma.
    Rioux-Leclercq N; Turlin B; Bansard J; Patard J; Manunta A; Moulinoux JP; Guillé F; Ramée MP; Lobel B
    Urology; 2000 Apr; 55(4):501-5. PubMed ID: 10736491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
    Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
    Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 is an independent prognostic factor in conventional renal cell carcinomas.
    Paradis V; Ferlicot S; Ghannam E; Zeimoura L; Blanchet P; Eschwége P; Jardin A; Benoît G; Bedossa P
    J Urol; 1999 Jun; 161(6):1984-7. PubMed ID: 10332486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
    Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
    Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration.
    Riddle ND; Gorden L; Rojiani MV; Hakam A; Rojiani AM
    Int J Clin Exp Pathol; 2010 Jun; 3(5):515-21. PubMed ID: 20606732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas.
    Sinik Z; Alkibay T; Ataoglu O; Biri H; Sözen S; Deniz N; Karaoglan U; Bozkirli I
    Int J Urol; 1997 Nov; 4(6):546-51. PubMed ID: 9477181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.